Clinical Trial

A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease

Name: A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease — clinical trial record (NCT07603050)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A phase I/II clinical study to evaluate the tolerance, safety and efficacy of VGN-R08b intracerebroventricular injection in patients with type III Gaucher's disease

Trial Details

NCT Number	NCT07603050
Lead Sponsor	Shanghai Vitalgen BioPharma Co., Ltd.
Conditions	Gaucher Disease Type 3
Enrollment	12 participants
Start Date	2026-05-14
Primary Completion	2028-05-29 (estimated)
Study Completion	2032-08-16 (estimated)
Updated on ClinicalTrials.gov	2026-05-22